Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%

MT Newswires Live

01-29

Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.

The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.

The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.

A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.

The firm's shares rose past 7% in recent Wednesday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2507215508"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507215508\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507215508?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507215508","market":"hk","top_or_hot":-1,"title":"Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-29 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNV.AU","symbol_name":"Renerve Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507215508","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507215508","pubTimestamp":1738125248,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Renerve  said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RNV.AU":"Renerve Ltd"},"translate_title":"Renerve表示2024年12月季度销售额增长260%；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNV.AU":0.9},"content_text":"Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}